Evidence map›Paper›PMID 35397689›Full record

ArticleMedical oncology (Northwood, London, England)2022

Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV.

Theres Fey, Nicole Erickson, Arndt Stahler, Maximilian Muenchhoff, Oliver T Keppler, Katharina Ruehlmann, Gabriele Krauss-Pfeiffer, Hannah Steinberg, Alexander Graf, Stefan Krebs and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Theres Fey *Comprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Nicole Erickson *Comprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany. nicole.erickson@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-0473-7689
Arndt StahlerDepartment of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Maximilian MuenchhoffMax von Pettenkofer Institute & Gene Center, Virology, National Reference Center for Retroviruses, Ludwig Maximilians University München, Pettenkoferstr. 9a, 80336, Munich, Germany.
Oliver T KepplerMax von Pettenkofer Institute & Gene Center, Virology, National Reference Center for Retroviruses, Ludwig Maximilians University München, Pettenkoferstr. 9a, 80336, Munich, Germany.
Katharina RuehlmannComprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Gabriele Krauss-PfeifferComprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Hannah SteinbergComprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Alexander GrafLaboratory for Functional Genome Analysis, Gene-Center, Ludwig Maximilians University, Munich, Germany.
Stefan KrebsLaboratory for Functional Genome Analysis, Gene-Center, Ludwig Maximilians University, Munich, Germany.
Helmut BlumLaboratory for Functional Genome Analysis, Gene-Center, Ludwig Maximilians University, Munich, Germany.
Elham KhatamzasCenter for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Sarah SeynstahlComprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Jozefina CasuscelliDepartment of Urology, Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Daniel MarkwardtDepartment of Gastroenterology, Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Roswitha ForstpointnerDepartment of Oncology and Hematology, Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Timo SchinkötheCANKADO Service GmbH, Cologne, Germany.
Michael von Bergwelt-BaildonDepartment of Oncology and Hematology, Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
Volker HeinemannComprehensive Cancer Center (CCC Munich LMU), Ludwig Maximilians University (LMU) Hospital, Munich, Germany.
LMU Klinikum · DELudwig-Maximilians-Universität München · DEGerman Center for Infection Research · DEHeidelberg University · DEHumboldt-Universität zu Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited knowledge exists on the effectiveness of preventive preparedness plans for the care of outpatient cancer patients during epidemics or pandemics. To ensure adequate, timely and continuous clinical care for this highly vulnerable population, we propose the establishment of preventive standard safety protocols providing effective early phase identification of outbreaks at outpatient cancer facilities and communicating adapted standards of care. The prospective cohort study Protect-CoV conducted at the LMU Klinikum from mid-March to June 2020 investigated the effectiveness of a rapid, proactive and methodical response to protect patients and interrupt SARS-CoV-2 transmission chains during the first pandemic wave. The implemented measures reduced the risk of infection of individual cancer patients and ensured safe adjunctive infusion therapy in an outpatient setting during the early COVID-19 pandemic. In addition to the immediate implementation of standard hygiene procedures, our results underscore the importance of routine PCR testing for the identification of asymptomatic or pre-symptomatic COVID-19 cases and immediate tracing of positive cases and their contacts. While more prospective controlled studies are needed to confirm these results, our study illustrates the importance of including preventative testing and tracing measures in the standard risk reduction procedures at all out patient cancer centers.

Indexed as

COVID-19PandemicsAmbulatory Care FacilitiesCohort StudiesHumansProspective StudiesRisk Reduction BehaviorSARS-CoV-2CancerCovid-19ImmunologyOutpatientPandemicSARS-CoV-2

Identifiers

PMID35397689
PMCPMC8994860
OpenAlexW4223591222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.